Abstract 215P
Background
Immunotherapy (IO) using programmed cell death protein 1 inhibitors is the standard of care in recurrent/metastatic head and neck cancer (R/M HNSCC). While response rate is almost 20% in the total population, a small percentage of patients shows exceptional response. Here, spatial whole transcriptome data were analysed to investigate potential compartment-specific associations of RNA expression with exceptional response to (IO).
Methods
Prospectively collected pre-treatment biopsies and clinicopathologic data of 50 IO-treated patients with R/M HNSCC were included in the study. Exceptional response (ER) was defined as complete or partial response (RECIST 1.1), lasting longer than 3 times the median response duration found in literature for the same treatment setting. Samples were evaluated using the GeoMx Human Whole Transcriptome Atlas (NanoString) assay for the in-situ quantification of 18,677 genes in the tumor (CK), leukocyte (CD45) and macrophage (CD68) tissue compartments. Differentially expressed genes (P<0.05, FDR 0.05) between ER and non-ER cases were identified in each compartment. Immune cell genes extracted from the “Single Cell RNA-Seq HNSCC” (CIBERSORTx) gene matrix and clinicopathologic characteristics; smoking, alcohol, sex, age, primary site and PD-L1 status, were investigated for correlations with ER.
Results
Seven exceptional responders were identified. Five immunoglobulin (Ig) genes (IGHG1, IGHG2, IGHG3, IGHG4, IGLL5) and one B-cell related gene (MZB1) showed the highest expression for exceptional responders both in the CD45 and CD68 compartments (stroma). Follicular dendritic cell secreted protein gene (FDCSP) was highly expressed in tumor. There was no association of ER with the immune-cell phenotypes derived from CIBERSORTx deconvolution. Alcohol consumption was the only clinicopathologic characteristic that showed association with ER (P=0.047).
Conclusions
ER to IO in R/M HNSCC is characterized by increased expression of Ig and B-cell related genes in tumor and stroma, indicating the importance of secreted immune factors for durable IO responses.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Rimm: Financial Interests, Personal, Advisory Board: AstraZeneca, Agendia, Cell Signaling Technology, Amgen, BMS, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, Konica/Minolta, GSK, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana; Financial Interests, Institutional, Funding: Amgen, Cepheid, NavigateBP, NextCure, Konica/Minolta. A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono, EPICS; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, Leo, Rakuten, eTheRNA immunotherapies, Merck Serono, Seagen, Merus, Merus Pharmaceuticals, GSK; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, Genesis, Incyte, Amgen, Debiopharm, MSD, Janssen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: Kura Oncology; Financial Interests, Personal, Steering Committee Member: Kura Oncology, GSK, Merus Pharmaceuticals; Financial Interests, Personal and Institutional, Funding: Kura Oncology, BMS, Roche, DEMO, Amgen, BI, Genesis, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer, GSK; Financial Interests, Personal, Other, Educational activity: Medscape, Prime Oncology; Financial Interests, Institutional, Local PI: Novartis, Replimune. All other authors have declared no conflicts of interest.
Resources from the same session
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract
99P - Real-world management of ir-colitis, a Danish 10-year cohort study
Presenter: Soeren Petersen
Session: Poster Display session
Resources:
Abstract
101P - Comparison on the effectiveness of multiple single and double immunotherapy treatments on advanced angiosarcoma patients: Meta analysis & systematic review
Presenter: Enzo Marson
Session: Poster Display session
Resources:
Abstract
102P - A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma after progression on first-line lenvatinib combined with PD-1 inhibitor
Presenter: Saifeng Li
Session: Poster Display session
Resources:
Abstract
103P - Tislelizumab combined with chemoradiotherapy for locally advanced esophageal squamous cell carcinoma: A multicenter, prospective, single-arm, real-world study
Presenter: zhihua wen
Session: Poster Display session
Resources:
Abstract
104P - The efficacy and safety of a novel PD-1/CTLA-4 bispecific antibody cadonilimab (AK104) as second- or later-line therapy for metastatic non-small cell lung cancer
Presenter: Hualin Chen
Session: Poster Display session
Resources:
Abstract
105P - A retrospective study using machine learning to analyze the effects of VEGFR-TKIs and PD-1 inhibitors as third-line or later treatment in patients with MSS mCRC
Presenter: Shumei Han
Session: Poster Display session
Resources:
Abstract
106P - Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
107P - Efficacy and safety of first-line TKI plus ICI therapy in metastatic non-clear cell renal cell carcinoma: A real-world multiple-centre study
Presenter: Yulu Peng
Session: Poster Display session
Resources:
Abstract
108P - Transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab versus TACE alone in patients with Barcelona Clinic liver cancer stage B unresectable hepatocellular carcinoma: A retrospective, propensity score-matched analysis
Presenter: Hongjie Cai
Session: Poster Display session
Resources:
Abstract